This study demonstrates that increased expression of (p) FADD is associated with a better local control in T1-T2 glottic squamous cell carcinoma of the larynx primarily treated with radiotherapy. These findings suggest that (p) FADD might be new prognostic biomarker to predict local recurrence after radiotherapy in early stage glottic carcinoma.
Summary
This study demonstrates that increased expression of (p) FADD is associated with a better local control in T1-T2 glottic squamous cell carcinoma of the larynx primarily treated with radiotherapy. These findings suggest that (p) FADD might be new prognostic biomarker to predict local recurrence after radiotherapy in early stage glottic carcinoma.
Introduction
In squamous cell carcinoma of the head-and-neck region (HNSCC), DNA amplification of the chromosome 11q13 region is observed in approximately 30% of all HNSCCs and is therefore one of the most frequently observed genomic abnormalities (1) . In HNSCC 11q13 amplification is associated with the presence of lymph node metastases, decreased disease-specific survival, and decreased overall survival (OS) (2) . Recently, we reported that the commonly amplified 11q13 region in oropharyngeal/laryngeal carcinomas contains at least 6 genes, FADD (Fas-associated death domain) (MORT1), PPFIA1 (LIPRIN), ORAOV1 (TAOS1), FGF19, cortactin (CTTN), and cyclin D1 (CCND1), that are amplified and overexpressed in almost all carcinomas with 11q13 amplification (3) . Of all genes in this 11q13 amplicon, FADD was not only amplified the most, but overexpression and amplification of FADD also correlated with increased FADD protein expression, suggesting that FADD is a key gene in the 11q13 amplicon (3) .
Originally, FADD (Fas [TNFRSF6]eassociated via death domain) was reported as a proapoptotic adaptor molecule that recruits caspases 8 and 10 to promote formation of the deathinducing signal complex (4) . The recruitment of these caspases to the death-inducing signal complex leads to intracellular processing and activation of caspases, eventually resulting in cleavage of downstream targets and apoptosis. More recently, an alternative function for FADD was described because many studies showed that FADD also plays an important role in growth and regulation of the cell cycle (5, 6) . Nuclear localization of FADD has been ascribed to FADD phosphorylation at Ser194 (pFADD), and the highest levels of pFADD are observed at the G2/M phase of the cell cycle (7) . In addition, treatment of cells in vitro with agents blocking the G2/M transition resulted in a significant accumulation of pFADD (8, 9) . Finally, expression of a Ser194ephospho-mimicking FADD mutant caused G2/M cell cycle arrest (9) . Altogether, these data suggest a key role for FADD/pFADD in cell cycle control. Because previous studies showed that cells arrested in the G2/M phase are most radiosensitive (10), FADD is amplified in more than 30% of HNSCCs, and pFADD is mainly expressed at the G2/M phase of the cell cycle, we hypothesize that glottic carcinomas with overexpression of pFADD will have better local control (LC) after radiotherapy alone.
In a series of 167 advanced-stage oropharyngeal/laryngeal carcinomas, we found that increased levels of both FADD and pFADD were significantly associated with a worse diseasespecific survival and positive lymph node status (3, 11) . In agreement with this finding, in HNSCC, FADD overexpression and pFADD overexpression in adenocarcinomas of the lung were both associated with decreased OS (12) . In prostate cancer, pFADD expression was associated with progression of disease (9) . In our series of 167 advanced-stage oropharyngeal/laryngeal carcinomas, we could not evaluate the prognostic value for LC after radiotherapy because of the presence of many confounding parameters that might influence the clinical outcome, such as the variety of different (combined) treatment modalities, different subsites in the head-and-neck region, and differences in extended disease (e.g., Nþ) and tumor size (3, 11) .
In this study we examined the prognostic value of FADD and pFADD expression in patients with laryngeal carcinoma primarily treated with radiotherapy alone. To evaluate the effect of FADD/ pFADD expression on clinical outcome after radiotherapy, we limited the number of possible interfering variables by selecting a homogeneous study population. Of all patients with laryngeal carcinoma treated at our institution between 1997 and 2004, we selected 92 patients with early-stage (pT1/pT2) glottic carcinoma of the larynx who were treated primarily with radiotherapy with curative intent. Because early-stage glottic carcinomas rarely have regional lymph node metastasis on initial diagnosis and because FADD expression has been associated with the presence of lymph node metastasis in advanced-stage HNSCC as well (11) , the analysis of early-stage glottic cancer will restrict our validation to LC after radiotherapy. Immunohistochemical staining of FADD and pFADD on pretreatment biopsy specimens will be correlated with LC and OS.
Methods and Materials

Patients and tissues
The selection of patients and samples was described in detail previously (13) . In brief, between 1997 and 2004, 638 patients were diagnosed with laryngeal squamous cell carcinoma in the northern part of the Netherlands (comprising >10 medical centers) and treated at our institute. Demographic and clinicopathologic data, such as sex, age, pretreatment hemoglobin level, T status, N status, and current and past tobacco use and alcohol use, were retrospectively collected by reviewing the patient charts. The inclusion criteria for this study were (1) histologically proven squamous cell carcinoma, (2) localization in the glottis, (3) cT1 and cT2, (4) no evidence of distant metastasis (cM0), (5) curative treatment with radiotherapy alone, and (6) no other previous treatment. From the 360 patients with T1/T2 glottic carcinomas, 157 formalin-fixed, paraffin-embedded pretreatment biopsy specimens were collected and revised by an experienced pathologist. Tissue specimens with sufficient tumor cells for immunohistochemical staining were available from 92 patients. The pretreatment characteristics are summarized in Table 1 . Informed consent was given by all patients included in the study.
Radiotherapy and follow-up
In all patients radiotherapy was delivered with megavoltage equipment by use of 6-MV photons as reported previously (13) . T1 tumors were treated with a total dose of 66 Gy at 2 Gy per fraction, 5 times per week. T2 tumors were generally treated with 6 fractions per week, to a total dose of 70 Gy in 6 weeks. In case of elective irradiation of the neck nodes, a total dose of 46 Gy was given on the primary planning target volume with an additional boost of 70 Gy on the primary tumor and pathologic lymph nodes (as detailed in the Appendix available online at redjournal.org).
After completing radiation, patients were followed up every 3 months in the first and second year and every 6 months in the third, fourth, and fifth year. After 5 years without evidence of disease, patients were discharged from follow-up. Twenty-one patients in whom a local recurrence developed after radiotherapy underwent salvage by total laryngectomy; one patient received palliative therapy because of inoperable recurrent tumor. A second primary developed in 9 patients (10%), in the lung (n Z 4), headand-neck region (n Z 4), or colon (n Z 1). During follow-up, 26 patients (28%), of whom 7 died of disease. All follow-up data are summarized in Table 2 .
Immunohistochemistry
Immunohistochemical staining and scoring for FADD, pFADD, cortactin, and cyclin D1 was performed as reported previously (3, 11) by use of the murine monoclonal antibody A66-2 (BD Biosciences, Franklin Lakes, NJ), rabbit polyclonal antibody against Ser194 pFADD (BD Biosciences), murine monoclonal antibody 30/cortactin (BD Biosciences), and rabbit anti-human monoclonal antibody SP4 (Lab Vision/Neomarkers, Fremont, CA), respectively (examples are shown in Fig. E1 available online at redjournal.org). For the scoring of the immunostaining of pFADD and cyclin D1, the percentage of tumor cells with nuclear staining was determined. Cutoff values of percentages for dichotomization for pFADD were determined by use of receiver operating curve analyses, and the best sensitivity/specificity ratio associated with LC was found at a cutoff level of 71%. Percentages of positive staining above the cutoff level were considered as high expression and those below as negative/low expression. Scoring was performed by two independent observers without knowledge of clinical data. The discordant cases were reviewed by all observers, and scores were reassigned on consensus of opinion. Detailed information is presented in the Appendix available online at redjournal.org.
Statistical analysis
Associations between expression of FADD, pFADD, cyclin D1, and cortactin were analyzed with a chi-square test. Follow-up time was calculated from the date of diagnosis until the date of the last follow-up visit. Local recurrence was defined as tumor recurrence at the primary tumor site and was calculated from the date of diagnosis until the date of local recurrence diagnosis or to the last follow-up. OS was defined from the date of diagnosis to the date of death or to last follow-up.
Kaplan-Meier survival analysis and Cox regression analysis adjusted for expression of FADD and pFADD, as well for sex, age, hemoglobin level, T status, N status, tobacco use, and alcohol use, were performed with LC and OS as endpoints. Only variables showing an association with LC or OS on univariate analysis (p < 0.10) were included in the multivariate Cox regression analysis. Alcohol consumption was excluded from the multivariate analysis because of the large number of missing values (17 missing [18%]). All statistical analyses were performed with SPSS software, version 16.0 (SPSS, Chicago, IL).
Results
FADD and pFADD are not associated with clinicopathologic features
Immunohistochemical staining of FADD was mainly cytoplasmic and very homogeneous across the tumor (Fig. E1A) . High levels of FADD were detected in 21 of 92 cases (23%). The (Figs. 1A and 1B ) . Interestingly, no local recurrence developed in any of the 12 patients with high expression of both FADD and pFADD, whereas a local recurrence developed in 22 of the 80 patients with low expression of either FADD, pFADD, or both (27.5%) (p Z 0.025) (Fig. 1C) . Multivariate Cox regression analysis showed that high pFADD expression was the strongest independent prognostic factor for LC after radiotherapy (HR, 2.72; 95% CI, 1.17e6.29; p Z 0.020) ( Table 4 ).
Expression of FADD or pFADD does not predict better OS
Kaplan-Meier survival analysis showed that high expression of FADD (p Z 0.213) and high expression of pFADD (p Z 0.788) were not associated with OS (Fig. 2) . Cox regression analysis also showed that high expression of FADD (HR, 1.94; 95% CI, 0.67e5.65; p Z 0.223) and high expression of pFADD (HR, 1.12; 95% CI, 0.49e2.55; p Z 0.788) were not associated with OS.
Cyclin D1 and cortactin are not associated with LC
Because cortactin and cyclin D1 are frequently co-amplified and consequently co-overexpressed with FADD in HNSCC (3, 11) and have been associated with poor prognosis and/or response to therapy (3, 14, 15) , we immunostained the same series for cortactin and cyclin D1 (examples are shown in Figs. E1C and E1D , available online at redjournal.org). Increased expression of cyclin D1 and cortactin was observed in 43 of 92 cases and 39 of 92 cases, respectively. Univariate Cox regression analysis (Table 3) and Kaplan-Meier survival analysis (Fig. E2 , available online at redjournal.org) showed that high expression of cyclin D1 and high expression of cortactin were not associated with LC in early-stage glottic cancer.
Discussion
Laryngeal squamous cell carcinoma is the most common type of HNSCC and accounts for approximately 20% of all newly diagnosed HNSCCs. Nowadays, most patients with Stage T1/T2 laryngeal carcinoma are treated with radiotherapy because of better laryngeal function after treatment compared with surgery. The 5-year LC and OS rates for T1/T2 laryngeal carcinoma vary between 69% and 94% and between 63% and 82%, respectively (16) . Unfortunately, except for TNM status, no good clinicopathologic factors are available to predict clinical outcome in early-stage laryngeal carcinoma treated with radiotherapy. The clinical relevance is obvious, because in case of recurrent disease after radiotherapy, salvage laryngectomy is mandatory, resulting in loss of vocal cord function and therefore quality of life. Thus molecular tumor markers could be useful to predict local recurrence and survival in patients with early-stage glottic carcinoma treated with radiotherapy.
Associations between expression of either FADD or pFADD with clinical outcome have been described in different tumor types. Chen et al. (12) showed that FADD overexpression and pFADD overexpression were both associated with decreased OS in patients with adenocarcinoma of the lung. Shimada et al. (9) reported that expression of pFADD was associated with progression of prostate carcinoma. In a previous study we found an association between FADD and pFADD expression and clinical outcome in a group of mainly advanced-stage laryngeal carcinomas (3, 11) . No associations could be performed between FADD/pFADD expression and response to therapy because of the heterogeneity of the patient series. In this study we selected a homogeneous series of patients with T1/T2 glottic carcinoma treated with radiotherapy only. Our data showed that high expression of FADD and, even more significantly, pFADD overexpression were associated with better LC. No association with OS was found. These data strongly suggest that overexpression of pFADD is associated with better radiosensitivity.
FADD is part of the chromosome 11q13 amplicon (3). We have shown that not only FADD but also several other genes in the amplicon (PPFIA1, TPCN2, FLJ442258, ORAOV1, FGF19, CTTN/cortactin, CCND1/cyclin D1) are overexpressed in HNSCC carcinomas with 11q13 amplification (3) . Two of these genes (cyclin D1 and cortactin) have been studied extensively (1) . Cyclin D1 has been associated with response to radiotherapy previously in breast cancer both in a clinical study (15, 17, 18) and in an in vitro model (14) , and cortactin has been associated with worse clinical outcome in HNSCC (11) and cell migration in vitro (19) . Immunostaining of the same series of 92 glottic cancers showed no association between either cortactin or cyclin D1 expression and LC (Table 3 and Fig. E2 ). The lack of this association for cyclin D1 is not consistent with the observed response to therapy in breast cancer but is concordant with studies in HNSCC that failed to associate cyclin D1 expression and clinical outcome (20) . In this study we only selected early-stage (T1/T2) glottic carcinomas, in which the rate of regional or distant metastasis is relatively low (only 1 of 92), which results from the less developed lymphatic drainage system of the glottic larynx. The lack of the observed association between cortactin and LC in this series of early-stage glottic carcinomas is therefore in good agreement with cortactin's function in cell migration and invasion (19) . This analysis showed that not cyclin D1 or cortactin but high pFADD expression is associated with LC in our series of earlystage glottic carcinomas.
Our data also suggest that the expression of pFADD might mediate the sensitivity of tumor cells to radiotherapy. However, at present, we can only speculate how. Besides the role of FADD in apoptosis, more recently, phosphorylation of FADD (pFADD) at serine 194 was reported to be involved in cell cycle progression (4, 5, 7, 8) and Alappat et al. (8) have shown that phosphorylation of FADD caused more cells to be arrested in the G2/M phase of the cell cycle. A possible explanation for this is that cells in the G2/M phase are more radiosensitive than cells in other phases of the cell cycle (10) . Furthermore, the fact that phosphorylation of FADD is associated with nuclear localization in our tumors and is involved in G2/M arrest in in vitro models (9) suggests that FADD plays an important role in sensitizing these tumors for radiation. However, whether pFADD itself triggers cells into G2/M arrest or cells at G2/M arrest show expression of pFADD has to be tested in future experiments by knocking down or expressing FADD and pFADD mutants in HNSCC cell lines and determining RT response directly by the classical clonogenic survival assay.
Conclusions
We showed that increased expression of pFADD/FADD is associated with better LC in early-stage glottic carcinoma treated with radiotherapy alone. A possible explanation is that pFADD expression is associated with more arrested cells in the radiosensitive G2/M phase of the cell cycle. Our findings suggest that pFADD might be a new prognostic biomarker to predict local recurrence in T1/T2 glottic carcinoma treated with radiotherapy.
